Asthma treatment guidelines recommend treatments that can control asthma and prevent exacerbation. However, despite the availability of effective medications, nearly 40 percent of the asthma population world-wide remains poorly controlled.
Colorado Springs, CO (PRWEB) September 10, 2013
Asthma & Allergy Associates, P.C. today announced that a member of its staff, Dr. Robert Nathan, has been invited to speak to selected specialists in allergy and pulmonary diagnosis and treatment. The presentations in Santiago, Chile, and Moscow, Russia, concern the results reported in his manuscript for Dulera 100/5, used for FDA approval of this drug.
Speaking of the study's results, Dr. Nathan, the lead investigator and author stated, "Asthma treatment guidelines recommend treatments that can control asthma and prevent exacerbation. However, despite the availability of effective medications, nearly 40 percent of the asthma population world-wide remains poorly controlled."
Continuing, Dr. Nathan points out that, "The rates of ER visits and hospitalizations due to asthma, nor unscheduled asthma-related office visits have not decreased from 1998."
To deal with this issue and as a follow-up to the study's results, Dulera, a combination of an inhaled steroid and long-acting bronchodilator is now being launched in the those countries in Latin America, Europe and Asia where more severe asthma has a higher prevalence. The goal of this initiative is to attempt to reduce flares that increase the cost of asthma care.
Since his leading role in the research and ultimate approval of Dulera by the FDA, Dr. Robert Nathan has been a highly-sought after global speaker, having been invited to Singapore, Hong Kong, Mexico, Panama and Brazil in addition to these newly-announced invitations.
Asthma is a chronic, or long-term, lung disease that inflames and narrows the airways. Asthma causes recurring periods of wheezing, a whistling sound when one breathes, shortness of breath, tightening of the chest and coughing. Coughing typically occurs at night or in the early morning. Although asthma predominantly starts in childhood, it does affect people of all ages. More than 22 million people in the United States have been reported to have asthma. Nearly 6 million of these individuals are children.
Nathan concluded his remarks with the observation that, "Unfortunately, cost is a growing factor on a global basis in providing effective medical treatments. We are excited that the success of our efforts means lower costs for asthma treatments and, as a result, more people receiving needed care and treatment."
For further information about the topic outlined in this release, please contact Dr. Nathan by phone or email listed below.
About Asthma & Allergy Associates, P.C.
Asthma & Allergy Associates, P.C. and Research Center is a Colorado practice specializing in the diagnosis of asthma and allergies, with offices in Colorado Springs, Pueblo and Cañon City. The specialists at the practice also perform the diagnosis and treatment of other problems, like sinusitis, skin disorders (Urticaria-Hives, Eczema), food allergy, and immune system disorders. Also associated with the practice is the Clinical Research Center that has been conducting pediatric and adult drug research for more than 25 years.
For more information about Asthma & Allergy Associates, P.C. please visit http://aacos.com
Toll Free: (800) 533-3900
E-mail: AllergyDrs@AACOS.com
Website: http://aacos.com/
We're here to help.
Call 1-866-640-6397
©Copyright 1997-, Vocus PRW Holdings, LLC.
Vocus, PRWeb, and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.
